Javier V. A.
- Country
- Spain
- Department
- 2106: Oftalmología
Research Overview
- Evaluation of Safety and Tolerability of Teprotumumab Dosing Durations in Patients with Thyroid Eye Disease: A Phase 3b/4 Randomized, Double-Masked, Multicenter Trial
- Open-Label Evaluation of VRDN-001 in Non-Responders with Thyroid Eye Disease from VRDN-001-101 and VRDN-001-301 Studies
- Efficacy and Safety Evaluation of Intravenous LASN01 in Thyroid Eye Disease: A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 38 of 68 partner sites.
Specializations
Endocrine Ophthalmology
The investigator specializes in the study and treatment of thyroid eye disease (TED), focusing on innovative therapeutic approaches for this challenging autoimmune condition.
- Advanced TED Treatment Protocols
- Orbital Inflammation Management
- Vision Protection Strategies
Their research encompasses comprehensive evaluation of novel biological therapies targeting the IGF-1 receptor pathway in TED patients.
Clinical Therapeutics
Expertise centers on developing and evaluating targeted biological treatments through both intravenous and subcutaneous administration routes for autoimmune eye disorders.
- Monoclonal Antibody Therapies
- Dose Optimization Studies
- Treatment Response Assessment
Their work includes investigating various dosing regimens to optimize therapeutic outcomes in orbital inflammatory conditions.
Disease Monitoring
The investigator focuses on clinical assessment methodologies for evaluating treatment efficacy in orbital disorders, particularly proptosis measurement and vision outcomes.
- Proptosis Evaluation
- Safety Monitoring Protocols
- Long-term Outcome Assessment
Their expertise includes developing standardized approaches for monitoring disease progression and treatment response.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.